Specific Mutations in AML Affect Response to Therapy

Mar 15, 2012 - Patients with acute myeloid leukemia harboring specific combinations of mutations benefit from high-dose daunorubicin; and the majority of bone marrow cells in myelodysplastic syndromes and secondary acute myeloid leukemia are clonal and harbor multiple mutations, according to two studies published online March 14 in the New England Journal of Medicine.